AlphAIAlphAI — Financial news for AI agents
Intellectia AIAPR 13 min read$TOVX

TOVX Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Theriva Biologics Inc (TOVX) as of March 31, 2026. It indicates a neutral overall technical sentiment based on a combination of moving averages and oscillators. Key metrics such as RSI, MACD, support, resistance levels, and various moving averages are detailed, offering insights into the stock's current trading position and potential future movements.

Original reporting
Intellectia AI
Published Apr 1, 2026, 7:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 7:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TOVX
Neutral
medium confidence
Mentioned
$TOVX
Relevance
6/10
AlphAI data visualization · based on Intellectia AI
Decision brief

The 30-second read

$TOVXNeutralLow
01

Why it matters

Current technical signals do not suggest a strong directional bias, indicating a wait-and-see approach may be prudent.

02

Market read

The analysis is primarily relevant for short-term traders and technical analysts; long-term investors should consider fundamental factors.

03

What to watch

Potential upcoming catalysts such as clinical trial results or regulatory decisions could significantly alter the stock's trajectory.

Relevance 6/10Timing: short-term

Background

This technical analysis is based on data as of March 31, 2026, focusing on recent price movements and technical indicators.

Company-level read

Ticker impact

$TOVXNeutralMedium confidence
Context

The article provides a technical analysis of Theriva Biologics Inc (TOVX), indicating a neutral technical sentiment based on moving averages and oscillators.

Expected impact

Likely minimal short-term price movement; potential for sideways trading.

Evidence & confidence

The analysis is based on standard technical indicators showing mixed signals, and no clear trend is established.

Market effects

Sector

Limited impact on the biotech or life sciences sector due to the neutral technical outlook.

Regional

No significant regional market effects expected.

Global

Minimal influence on global markets; specific to TOVX's trading activity.

Counterpoint

What could challenge this read

If positive news or fundamental developments emerge, TOVX could break out of the neutral zone and trend upward.

Key entities

  • Company
    Theriva Biologics Inc

    A biotech company focused on developing targeted therapies.

Read at source← All news

Related articles

SEP 30
$TOVXHighAI 9/10

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Theriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.

globenewswire.com2 min
AUG 11
$TOVXMed

Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr

SEC EDGAR 8-K4 min
AUG 6
$TOVXMed

Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patient

Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.

finanznachrichten.de4 min
JUL 7
$TOVXMedAI 8/10

Theriva Biologics, Inc.: Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) i

Theriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.

finanznachrichten.de2 min